What are the main financial results being reported by Eli Lilly in this 8-K?

This 8-K report announces the results of operations for Eli Lilly & Company for the quarter and full year ended December 31, 2005. It includes an income statement for these periods and a consolidated balance sheet as of December 31, 2005. The details of these results are provided in an attached press release.

Why is Eli Lilly using non-GAAP financial measures?

Eli Lilly uses non-GAAP measures like adjusted net income and adjusted diluted earnings per share to provide investors with a clearer view of its ongoing operations. These measures exclude significant, often unpredictable charges and accounting changes, which can distort period-over-period comparisons and mask underlying business trends.

What specific items are excluded when calculating Eli Lilly's non-GAAP financial results?

The exclusions typically include asset impairment, restructuring and other special charges recognized in Q4 2005, the cumulative effect of adopting new accounting rule FIN 47, a product liability charge from Q2 2005, various charges from Q4 2004 (including those related to the American Jobs Creation Act and R&D in-licensing), and asset impairment charges from Q2 2004 and R&D acquisition costs from Q1 2004.

What is the significance of the adoption of SFAS 123R (Statement of Financial Accounting Standards No. 123 revised 2004 — Share-Based Payment)?

Eli Lilly adopted the new accounting standard for share-based payments starting January 1, 2005. To facilitate a comparable year-over-year analysis, the company has provided adjusted pro-forma earnings per share for 2004, assuming this new accounting standard had been applied retroactively to the beginning of 2004.

LLY 8-K: Earnings & Results

Summary

Eli Lilly & Co. (LLY) filed an 8-K report on January 26, 2006, to announce its financial results for the fourth quarter and full year ended December 31, 2005. The report highlights the company's use of non-GAAP financial measures, such as adjusted net income and diluted earnings per share, to provide a clearer picture of ongoing operations by excluding certain significant charges and accounting changes. These adjustments allow for more meaningful period-over-period comparisons and trend analysis, which management utilizes for internal evaluation and resource allocation. The filing also includes financial expectations for the full year 2006, presented on both a GAAP and an adjusted basis.

Key Highlights

1Announcement of Q4 and Full Year 2005 financial results for Eli Lilly & Co.
2Company utilizes non-GAAP financial measures (adjusted net income, adjusted EPS) for enhanced operational clarity.
3Exclusions from non-GAAP measures include asset impairment, restructuring charges, and accounting changes (FIN 47).
4Specific charges from prior periods (Q2 2005 product liability, Q4 2004 charges, Q2 2004 impairments, Q1 2004 R&D acquisition) are also excluded for comparative purposes.
5Adoption of new accounting standard for share-based payments (SFAS 123R) starting January 1, 2005, with pro-forma adjustments for 2004 for comparable analysis.
6Provided financial expectations for Full Year 2006, including both GAAP and adjusted EPS guidance.
7Management emphasizes that non-GAAP measures are supplementary and should be considered alongside GAAP financial statements.

ELI LILLY & Co 8-K Report, Financial Results (Jan 26, 2006)

Summary

Key Highlights

Frequently Asked Questions